Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
- 12 June 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 145 (6), 871-878
- https://doi.org/10.1093/ajcp/aqw045
Abstract
Objectives: Recent studies have shown strong correlation of pathological complete response (pCR) to neoadjuvant chemotherapy with survival and prognosis in breast cancers. Methods: Clinical data from 237 breast cancer patients who received neoadjuvant chemotherapy between 2012 and 2014 were reviewed . Correlations were sought between pCR and estrogen receptor (ER), progesterone receptor (PR), and HER2 status; Nottingham and nuclear grades; tumor tubule formation; mitotic score; Ki67 index; and tumoral and stromal lymphocytic infiltration (TLI and SLI, respectively). Results: Of the 237 cases, 104 (43.9%) achieved pCR. The HER2+ and triple negative breast cancer (TNBC) subtypes had higher pCR rates compared with the luminal subtype (ER+ or PR+ and HER2–). ER and PR negativity, HER2 positivity, Nottingham grade 3, increased TLI and SLI, high mitotic count and Ki67 score correlated significantly with pCR in the overall cohort. TLI and SLI correlated significantly with pCR in the HER2+ and TNBC subtypes in multivariate analysis, whereas no biomarkers correlated with pCR in the luminal subtype. Conclusions: In addition to the pathologic parameters and biomarkers already routinely assessed, evaluation of TLI and SLI may help to better select patients with HER2+ and TNBC for neoadjuvant chemotherapy.Keywords
This publication has 37 references indexed in Scilit:
- Neoadjuvant Therapy in the Treatment of Breast CancerSurgical Oncology Clinics of North America, 2014
- Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerBritish Journal of Cancer, 2013
- Response-Guided Neoadjuvant Chemotherapy for Breast CancerJournal of Clinical Oncology, 2013
- Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?The Breast, 2013
- Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/EthnicityJAMA Surgery, 2013
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapyEuropean Journal Of Cancer, 2012
- Pathological Complete Response and Accelerated Drug Approval in Early Breast CancerNew England Journal of Medicine, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial.Cancer Research, 2011